QQQ   432.79 (+0.19%)
AAPL   188.32 (-0.58%)
MSFT   414.11 (+0.01%)
META   470.00 (+0.09%)
GOOGL   145.91 (+0.25%)
AMZN   169.84 (-0.40%)
TSLA   189.56 (+1.06%)
NVDA   696.41 (-0.65%)
NIO   5.82 (-0.68%)
AMD   169.35 (-0.93%)
BABA   70.74 (-3.94%)
T   16.82 (-2.94%)
F   12.83 (+0.23%)
MU   84.88 (-0.34%)
CGC   4.11 (-4.86%)
GE   139.07 (+0.41%)
DIS   110.54 (+11.50%)
AMC   4.09 (+3.81%)
PFE   27.56 (+0.00%)
PYPL   56.13 (-11.24%)
XOM   103.97 (+1.71%)
QQQ   432.79 (+0.19%)
AAPL   188.32 (-0.58%)
MSFT   414.11 (+0.01%)
META   470.00 (+0.09%)
GOOGL   145.91 (+0.25%)
AMZN   169.84 (-0.40%)
TSLA   189.56 (+1.06%)
NVDA   696.41 (-0.65%)
NIO   5.82 (-0.68%)
AMD   169.35 (-0.93%)
BABA   70.74 (-3.94%)
T   16.82 (-2.94%)
F   12.83 (+0.23%)
MU   84.88 (-0.34%)
CGC   4.11 (-4.86%)
GE   139.07 (+0.41%)
DIS   110.54 (+11.50%)
AMC   4.09 (+3.81%)
PFE   27.56 (+0.00%)
PYPL   56.13 (-11.24%)
XOM   103.97 (+1.71%)
QQQ   432.79 (+0.19%)
AAPL   188.32 (-0.58%)
MSFT   414.11 (+0.01%)
META   470.00 (+0.09%)
GOOGL   145.91 (+0.25%)
AMZN   169.84 (-0.40%)
TSLA   189.56 (+1.06%)
NVDA   696.41 (-0.65%)
NIO   5.82 (-0.68%)
AMD   169.35 (-0.93%)
BABA   70.74 (-3.94%)
T   16.82 (-2.94%)
F   12.83 (+0.23%)
MU   84.88 (-0.34%)
CGC   4.11 (-4.86%)
GE   139.07 (+0.41%)
DIS   110.54 (+11.50%)
AMC   4.09 (+3.81%)
PFE   27.56 (+0.00%)
PYPL   56.13 (-11.24%)
XOM   103.97 (+1.71%)
QQQ   432.79 (+0.19%)
AAPL   188.32 (-0.58%)
MSFT   414.11 (+0.01%)
META   470.00 (+0.09%)
GOOGL   145.91 (+0.25%)
AMZN   169.84 (-0.40%)
TSLA   189.56 (+1.06%)
NVDA   696.41 (-0.65%)
NIO   5.82 (-0.68%)
AMD   169.35 (-0.93%)
BABA   70.74 (-3.94%)
T   16.82 (-2.94%)
F   12.83 (+0.23%)
MU   84.88 (-0.34%)
CGC   4.11 (-4.86%)
GE   139.07 (+0.41%)
DIS   110.54 (+11.50%)
AMC   4.09 (+3.81%)
PFE   27.56 (+0.00%)
PYPL   56.13 (-11.24%)
XOM   103.97 (+1.71%)
OTCMKTS:LZAGY

Lonza Group (LZAGY) Stock Price, News & Analysis

$51.07
+1.11 (+2.22%)
(As of 02/8/2024 ET)
Compare
Today's Range
$50.71
▼
$51.12
50-Day Range
$36.99
▼
$51.32
52-Week Range
$34.19
▼
$66.00
Volume
209,423 shs
Average Volume
304,736 shs
Market Capitalization
$38.03 billion
P/E Ratio
N/A
Dividend Yield
0.18%
Price Target
N/A
Stock AnalysisAnalyst ForecastsChartDividendFinancialsHeadlinesInsider TradesSEC FilingsShort Interest

Lonza Group MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.01% of Shares Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
0.50mentions of Lonza Group in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
12.66%
From $1.58 to $1.78 Per Share

Overall MarketRank™

New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.46 out of 5 stars

See Top Rated MarketRank™ Stocks Here

LZAGY stock logo

About Lonza Group Stock (OTCMKTS:LZAGY)

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. It supports customers across various aspects of design, development, and manufacturing. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies. It also offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. In addition, this segment provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. The company was incorporated in 1897 and is headquartered in Basel, Switzerland.

LZAGY Stock Price History

LZAGY Stock News Headlines

February 4, 2024 | americanbankingnews.com
Deutsche Bank Aktiengesellschaft Upgrades Lonza Group (OTCMKTS:LZAGY) to "Buy"
February 2, 2024 | uk.investing.com
Lonza Group AG (LONNz)
February 8, 2024 | DTI (Ad)
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
January 28, 2024 | seekingalpha.com
Lonza: Excellent Growth Projections Will Sharply Increase Free Cash Flow
January 27, 2024 | finance.yahoo.com
Lonza Group Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
January 26, 2024 | morningstar.com
Lonza Shares Rise on Sales, Earnings Beat
January 26, 2024 | msn.com
Lonza long-time chairman to exit; shares gain
January 26, 2024 | finance.yahoo.com
UPDATE 2-Lonza chairman to step down, drugmaker confirms targets, shares soar
February 8, 2024 | The Oxford Club (Ad)
Better Than Oil Stocks
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. 
January 26, 2024 | finance.yahoo.com
Lonza chairman to step down, drugmaker confirms targets, shares soar
January 26, 2024 | finance.yahoo.com
Lonza Sees Flat Sales in 2024
January 19, 2024 | finance.yahoo.com
A Look At The Fair Value Of Lonza Group AG (VTX:LONN)
January 17, 2024 | bizjournals.com
East Bay drug manufacturer to close facility it bought in 2017, cut 218 jobs
November 13, 2023 | finance.yahoo.com
Lonza Group AG (VTX:LONN) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
November 10, 2023 | morningstar.com
Lonza Group Ltd ADR LZAGY
November 6, 2023 | markets.businessinsider.com
Lonza Prices CHF 400 Million Dual-Tranche Straight Bonds
November 3, 2023 | morningstar.com
Lonza Group Ltd LONN
October 26, 2023 | finance.yahoo.com
Individual investors who have a significant stake must be disappointed along with institutions after Lonza Group AG's (VTX:LONN) market cap dropped by CHF2.2b
October 5, 2023 | finance.yahoo.com
Investors in Lonza Group (VTX:LONN) have seen respectable returns of 39% over the past five years
October 4, 2023 | msn.com
Lonza Group AG - ADR (LZAGY) Price Target Increased by 24.47% to 263.63
September 19, 2023 | finance.yahoo.com
UPDATE 2-Moderna to cut mRNA drug substance production at Lonza facility
September 18, 2023 | finance.yahoo.com
UPDATE 2-Swiss drug ingredient maker Lonza's CEO to leave
September 18, 2023 | finance.yahoo.com
Lonza CEO Pierre-Alain Ruffieux to Leave
September 13, 2023 | finance.yahoo.com
ABL Bio Taps into Synaffix ADC Technology to Accelerate Development of Bispecific ADC Products
August 11, 2023 | finance.yahoo.com
Is Lonza Group AG (VTX:LONN) Worth CHF498 Based On Its Intrinsic Value?
August 2, 2023 | msn.com
Lonza Group AG - ADR (LZAGY) Price Target Increased by 19.33% to 201.84
July 27, 2023 | finance.yahoo.com
Lonza Group AG Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
See More Headlines
Receive LZAGY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lonza Group and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
2/08/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Tobacco products
Sub-Industry
N/A
Current Symbol
OTCMKTS:LZAGY
CUSIP
N/A
CIK
1446711
Web
www.lonza.com
Phone
(161) 316-8111
Fax
41-61-316-9111
Employees
17,494
Year Founded
1897

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
31.62
P/E Growth
2.76
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
0.27
Current Ratio
1.77
Quick Ratio
1.36

Sales & Book Value

Annual Sales
$7.48 billion
Price / Sales
4.98
Cash Flow
$2.02 per share
Price / Cash Flow
24.73
Book Value
$14.23 per share
Price / Book
3.51

Miscellaneous

Outstanding Shares
744,690,000
Free Float
744,167,000
Market Cap
$37.20 billion
Optionable
Not Optionable
Beta
0.96

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover
10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Albert M. Baehny (Age 72)
    Interim CEO & Chairman
    Comp: $370.97k
  • Mr. Philippe Deecke (Age 52)
    Chief Financial Officer
  • Ms. Maria Soler Nunez (Age 55)
    Head of Group Operations
  • Mr. Dirk Oehlers
    Vice President of Investor Relations
  • Mr. Andreas Bohrer
    Group General Counsel & Company Secretary
  • Ms. Victoria Morgan
    Head of External Communications
  • Ms. Jennifer Clancy
    Senior Director of Global Marketing

Key Competitors

View All Competitors

Should I Buy Lonza Group Stock? LZAGY Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Lonza Group was last updated on Thursday, February 1, 2024 at 2:00 PM.

Pros

Here are some ways that investors could benefit from investing in Lonza Group AG:

  • Lonza Group AG has shown consistent revenue growth over the past year, indicating a strong business performance.
  • The company has a diverse portfolio of products and services, which helps mitigate risks associated with relying on a single product or market.
  • Lonza Group AG has a strong track record of innovation and product development, allowing it to stay competitive in the market.
  • The company has a solid financial position with a healthy balance sheet and strong cash flow, providing stability and potential for future growth.
  • Lonza Group AG's stock price has been steadily increasing, indicating positive investor sentiment and potential for capital appreciation.

Cons

Investors should be bearish about investing in Lonza Group AG for these reasons:

  • The company operates in a highly competitive industry, which may pose challenges in maintaining market share and profitability.
  • Lonza Group AG's business operations are subject to regulatory and compliance risks, which could impact its ability to operate and generate revenue.
  • Fluctuations in raw material prices could affect the company's profitability and margins.
  • The global economic conditions and geopolitical uncertainties may impact Lonza Group AG's business operations and financial performance.
  • Investing in Lonza Group AG involves market risk, and the stock price may be influenced by factors beyond the company's control.














LZAGY Stock Analysis - Frequently Asked Questions

Should I buy or sell Lonza Group stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lonza Group in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" LZAGY shares.
View LZAGY analyst ratings or view top-rated stocks.

How have LZAGY shares performed in 2024?

Lonza Group's stock was trading at $42.09 at the start of the year. Since then, LZAGY shares have increased by 21.3% and is now trading at $51.07.
View the best growth stocks for 2024 here.

Are investors shorting Lonza Group?

Lonza Group saw a increase in short interest during the month of January. As of January 15th, there was short interest totaling 49,200 shares, an increase of 1,657.1% from the December 31st total of 2,800 shares. Based on an average daily trading volume, of 136,200 shares, the days-to-cover ratio is presently 0.4 days.
View Lonza Group's Short Interest.

How often does Lonza Group pay dividends? What is the dividend yield for Lonza Group?

Lonza Group declared a dividend on Thursday, May 4th. Investors of record on Wednesday, May 10th will be paid a dividend of $0.108 per share on Friday, May 26th. This represents a yield of 0.17%. The ex-dividend date of this dividend is Tuesday, May 9th. This is an increase from the stock's previous dividend of $0.09.
Read our dividend analysis for LZAGY.

Is Lonza Group a good dividend stock?

Lonza Group (OTCMKTS:LZAGY) pays an annual dividend of $0.09 per share and currently has a dividend yield of 0.17%.
Read our dividend analysis for LZAGY.

How do I buy shares of Lonza Group?

Shares of LZAGY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Lonza Group have any subsidiaries?
The following companies are subsidiares of Lonza Group: Arch Acquisition LLC, Arch Chemicals Canada Inc., Arch Chemicals Inc., Arch Chemicals Limited, Arch Chemicals Receivables LLC, Arch Chemicals SAS, Arch Personal Care Products L.P., Arch Protection Chemicals Private Limited, Arch Quimica Argentina S.R.L., Arch Quimica Brasil Ltda., Arch Timber Protection B.V., Arch Treatment Technologies Inc., Arch UK Biocides Limited, Arch Water Products France S.A.S., Arch Water Products South Africa (Pty) Ltd, Arch Wood Protection (Aust) Pty Ltd, Arch Wood Protection (M) Sdn. Bhd., Arch Wood Protection (NZ) Limited, Arch Wood Protection (SA) Pty Ltd, Arch Wood Protection Canada Corp., Arch Wood Protection Inc, Bend Research Inc., BioAtrium AG, CH Capsules Malaysia SDN BHD, Capsugel, Capsugel (Thailand) Co. Ltd, Capsugel Australia Pty Ltd, Capsugel Belgium NV, Capsugel Brasil Importação e Distribuição de Insumos Farmacêuticos e Alimentos Ltda., Capsugel Canada Corp., Capsugel Distribucion S. de R.L. de C.V., Capsugel FinanceCo II S.à r.l., Capsugel FinanceCo S.C.A., Capsugel FinanceCo S.à r.l, Capsugel France Holdings SAS, Capsugel France SAS, Capsugel Funding LLC, Capsugel Germany GmbH, Capsugel Healthcare Private Limited, Capsugel Holdings (Hong Kong) Limited, Capsugel Holdings S.à r.l., Capsugel Holdings US Inc., Capsugel Hungary Kft, Capsugel Inc., Capsugel Italy S.R.L., Capsugel Japan Inc., Capsugel Manufacturing Inc., Capsugel Middle East Sàrl, Capsugel New Zealand Limited, Capsugel Pharmaceutical and Health Products Marketing Ltd, Capsugel Philippines Inc., Capsugel Ploermel SAS, Capsugel S.à r.l., Capsugel Spain S.L., Capsugel US LLC, Capsugel de México S. de R.L. de C.V., Diacon Technologies, Diacon Technologies Limited, Hickson Ltd, InterHealth Nutraceuticals, InterHealth Nutraceuticals Incorporated, LLC Capsugel, Lonza (China) Investments Co. Ltd., Lonza AG, Lonza America Inc., Lonza Argentina S.A, Lonza Biologics Inc., Lonza Biologics Porriño S.L., Lonza Biologics Tuas Pte. Ltd, Lonza Biologics plc, Lonza Bioscience SARL, Lonza Bioscience Singapore Pte Ltd, Lonza Biotec s.r.o., Lonza Cologne GmbH, Lonza Colombia S.A.S, Lonza Copenhagen ApS, Lonza Costa Rica S.A., Lonza Geleen B.V., Lonza Guangzhou Ltd, Lonza Guangzhou Nansha Ltd, Lonza Houston Inc., Lonza Inc., Lonza India Private Limited, Lonza Israel Ltd, Lonza Japan Ltd, Lonza Luxembourg S.à r.l., Lonza Microbial Control Asia Pacific Pte Ltd, Lonza Milano S.r.l., Lonza NZ Limited, Lonza Nanjing Ltd, Lonza Netherlands B.V, Lonza Rockland Inc., Lonza Sales AG, Lonza Shanghai International Trading Ltd, Lonza Suzhou Ltd, Lonza Swiss Finanz AG, Lonza Swiss Licences AG, Lonza Verviers SPRL, Lonza Walkersville Inc., Lonza do Brasil Especialidades Quimicas Ltda., MW Encap (Holdings) Limited, MW Encap Limited, Micro-Macinazione, Micro-Macinazione SA, Octane Biotech, Octane Biotech Inc, P.T. Capsugel Indonesia, PharmaCell, Powdersize LLC, Suzhou Capsugel Limited (JV), Triangle Research Labs, Xcelience Clinical Services Ltd, Xcelience LLC, and Zelam Holdings.
Read More
This page (OTCMKTS:LZAGY) was last updated on 2/8/2024 by MarketBeat.com Staff

My Account -